

(English version)

**Question for written answer E-002146/24
to the Commission
Gerald Hauser (P/E)
(17 October 2024)**

Subject: Follow-up question on Mpox

Part of Stella Kyriakides' reply to my previous question on Mpox vaccines reads as follows:

‘In 2022, the Commission purchased 334,540 doses of the MVA-BN vaccine (called Jynneos in the United States and Imvanex in the EU) ... The Commission also concluded framework contracts ... to purchase up to 2 million doses of vaccine until the end of 2024 and 10 million courses of the therapeutic Tecovirimat SIGA until mid-2026.’

After the World Health Organisation had declared a global public health emergency on 14 August 2024, the Commission donated 215 420 doses of vaccine to Africa via the Africa Centres for Disease Control and Prevention. The Commission is coordinating the response of the EU and its Member States through ‘Team Europe’. As such, Member States have pledged to donate an additional 360 000 doses of the Mpox vaccine to Africa, once an acceptance and distribution agreement has been sealed with the recipient countries.

1. How much did the Commission pay to purchase the Mpox vaccines?
2. How much will it cost to purchase the Mpox vaccines and Tecovirimat SIGA treatment kits by the end of 2026?

Submitted: 17.10.2024

**Answer given by Ms Lahbib on behalf of the European Commission
(7 January 2025)**

The Commission is not in a position to disclose the requested information about the price paid under the Commission contract for Mpox vaccines, neither about the contracts that were signed under the Joint procurement Agreement for Mpox vaccines and the Mpox therapeutic Tecovirimat.

The disclosure of the price per unit would undermine the protection of commercial interests of the contractor, which is also protected by confidentiality obligations set out in the contracts.
